الفهرس | Only 14 pages are availabe for public view |
Abstract Aim of the work To assess the role of microalbuminuria as a predictor of silent ischemia in asymptomatic type II diabetic patients. The following are the result of our study: • The prevelance of SMI is 23 % of our patients. • There was significant difference between the two groups in severity of ischemia as semiquantified by WMSI (1.43 in ischemic patients in group I Versus 1.22 in ischemic patients in group II (P value 0.019). • There was significant difference between the two groups in the peak systokic strain rate at peak stress which is lower in group I versus group II (-2.95±0.37 versus -2.62 ± 0.22, P value 0.045). • There was significantly lower difference in strain rate between peak stress and rest in group I compared to group II (-1.27±0.22 Versus -1.41 ± 0.27 , P value 0.027 ) • There was trend to lower difference between peaks and resting velocity in group I compared to group II (3.8805 ± 1.8 Versus 2.5475 ± 2.6, p value 0.067). • There is significant difference between patients with positive dobutamine echocardiography and patients with negative test in microalbuminuria, age, dyslipifemia, duration of diabetes and gkycemic control. Conclusion Based on results shown in this study we can conclude that: • The prevelance of SMI in our study is 23 % of our patients. However the exact prevalence of silent myocardial ischemia in asymptomatic diabetic patients is difficult to determine. A wide range between 4% and 57% has been reported. • Microalbuminura, duration of diabetes, UN controlled DM, obesity and dyslipidemia are a significant predictors of silent ischemia. • Diabetic subjects with microalbuminuria had diminished longitudinal myocardial contractility assessed by strain rate (peak stress peak systolic SR and difference between peak stress peak systolic SR and resting peak systolic SR) compared with normalbuminuric group. |